L&T Technology Services Launches NVIDIA-Powered AI Lung Digital Twin Platform for Advanced Respiratory Diagnostics

Key Takeaways

• LTTS launches AI lung digital twin platform.
• Powered by NVIDIA Omniverse, TensorRT, MONAI.
• Provides 3D CT visualization and automated segmentation.
• Reduces pre‑operative planning time, enhances procedural safety.

Pulse Analysis

Digital twins are reshaping how clinicians interact with patient data, moving beyond static images to dynamic, manipulable replicas. In the context of pulmonary medicine, LTTS’s new platform builds on its MedTech expertise to transform conventional CT scans into fully simulated lung models. This capability aligns with broader industry trends where AI‑driven visualization tools are becoming essential for complex procedures, offering clinicians a more intuitive understanding of anatomy and pathology.

The technical backbone of the solution rests on NVIDIA’s Physical AI ecosystem. Omniverse provides a collaborative, photorealistic environment for real‑time 3D interaction, while MONAI accelerates medical image segmentation, automatically delineating airways, vessels, and lesions. TensorRT optimizes inference speed, ensuring that deep‑learning models run swiftly enough for clinical workflows. Together, these components deliver a seamless pipeline from raw imaging data to an interactive digital twin, reducing latency and supporting rapid decision‑making during bronchoscopy and biopsy planning.

From a market perspective, the launch signals a maturing convergence of AI, cloud infrastructure, and healthcare delivery. As lung cancer and COPD prevalence rises, hospitals seek tools that can shorten planning cycles, lower complication rates, and personalize treatment pathways. LTTS’s partnership with NVIDIA showcases a replicable model for other organ systems, potentially spurring a wave of AI‑enhanced digital twins across radiology, cardiology, and orthopedics. Early adopters stand to gain competitive advantage through improved patient outcomes and operational cost savings, while the broader ecosystem benefits from validated use cases that drive further investment in precision‑medicine technologies.